| Literature DB >> 23385235 |
Alba Naudí1, Mariona Jové, Victòria Ayala, Rosanna Cabré, Manuel Portero-Otín, Reinald Pamplona.
Abstract
Non-enzymatic modification of aminophospholipids by lipid peroxidation-derived aldehydes and reducing sugars through carbonyl-amine reactions are thought to contribute to the age-related deterioration of cellular membranes and to the pathogenesis of diabetic complications. Much evidence demonstrates the modification of aminophospholipids by glycation, glycoxidation and lipoxidation reactions. Therefore, a number of early and advanced Maillard reaction-lipid products have been detected and quantified in different biological membranes. These modifications may be accumulated during aging and diabetes, introducing changes in cell membrane physico-chemical and biological properties.Entities:
Year: 2013 PMID: 23385235 PMCID: PMC3588044 DOI: 10.3390/ijms14023285
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1General structures of principal reactive carbonyl species detected in biological systems.
Figure 2Protein, DNA and aminophospholipid damage resulting from carbonyl products of lipid peroxidation. Shown are examples of molecular adducts (Advanced Lipoxidation Endproducts, ALEs) generated by the reactive carbonyl compound glyoxal.
Summary of studies addressing the characterization of non-enzymatic aminophospholipid modification by carbonyl-amine reactions.
| Experimental model | Analytical approach | Structural characterization | Ref. |
|---|---|---|---|
| Peroxidation of arachidonate and docosahexaenoate + synthetic dipalmitoyl phosphatidylethanolamine | Fluorimeter | Fluorescence chromophores (Ex 360 nm, Em 430 nm) | [ |
| Rat liver mitochondrial and microsomal fractions peroxidized | Fluorimeter | Fluorescent chromophores (Ex 365–370 nm, Em 435–440 nm) | [ |
| Methyl arachidonate/methyl linolenate/methyl linoleate/Malondialdehyde + phosphatidylethanolamine/phosphatidylserine (PE/PS) | Fluorimeter | Fluorescent chromophores (Ex 365 nm, Em 435 nm) | [ |
| Malondialdehyde + Red blood Cells (RBC) | Fluorimeter | Fluorescent chromophores (Ex 390–400 nm, Em 460 nm) | [ |
| Lipid peroxidation of rat liver microsomes | Fluorimeter | Fluorescent chromophores (Ex 359 nm, Em 430 nm) | [ |
| Lipid peroxidation-derived compounds | Fluorimeter | Fluorescent chromophores (Ex 360 nm, Em 435 nm) | [ |
| Malondialdehyde + primary amines | Fluorimeter | Identification of 1–4-Dihydropyridine-3,5-Dicarbaldehydes as model of fluorescent components in lipofuscin (Ex 375–405 nm, Em 435–465 nm) | [ |
| 4-Hydroxynonenal (4-HNE) + microsomes/mictochondria/phospholipids (PS and PE) | Fluorimeter | Fluorescent chromophores (Ex 360 nm, Em 430 nm) | [ |
| Malondialdehyde (MDA) + serine | Nuclear magnetic resonance (NMR) and (high performance liquid chromatography (HPLC) | [ | |
| MDA + ethanolamine | NMR and HPLC | [ | |
| Mixed liposomes of | Fluorimeter and oxygen consumption monitored polarographically with a Clark-type oxygen probe | Fluorescent chromophores (Exc 360 nm, Em 430 nm) | [ |
| Glucose + PE and PS | Liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS and TLC) | Glycated aminoglycerophospholipids | [ |
| Lens + oxidative conditions | Fluorimeter and TLC | MDA:aminophospholipid adducts (Ex 360 nm, Em 470 nm) | [ |
| Glycoxidation and autoxidation of PE from RBCs | Gas chromatography-mass spectrometry (GC-MS) | Carboxymethyl-ethanolamine (as marker of carboxymethyl-phosphatidylethanolamine, CM-PE) | [ |
| Glucose + phosphatidylethanolamine | Gas-liquid chromatography-mass spectrometry (GLC-MS) and HPLC with diode-array detection (DAD) | 1-deoxy-1-(2-hydroxyethylamino)- | [ |
| Glucose + PE/phosphatidylcholine (PC)-PE liposomes | Thin layer chromatography (TLC), HPLC, NMR, fast atomic bombardment (FAB)-MS | Deoxy- | [ |
| (2-aminoethyl)phenetydylphosphate and (2-aminoethyl)ethylphosphate as model of aminophospholipids + carbohydrates | HPLC, NMR | Aminophospholipid glycation | [ |
| PE and PS + glucose | GC-MS | [ | |
| Human low density lipoprotein (hLDL) + p-hydroxyphenylacetaldehyde (p-hydroxyphenylacetaldehyde (pHA), product of | GC-MS | pHA-ethanolamine | [ |
| Glucose and 3-Deoxyglucosone + PE | GLC-MS and HPLC-DAD | Formation of a phospholipid-linked pyrrolecarbaldehyde | [ |
| Carbohydrates + PE | LC-ESI-MS, HPLC-DAD, and NMR | PE-derived Amadori compounds | [ |
| PE + 4,5(E)-epoxy-2(E)-heptenal (secondary product of lipid peroxidation) | GC-MS, HPLC-MS, NMR | Phosphatidylethanolpyrroles and phosphatidylethanol-2-(1-hydroxypropyl)pyrroles | [ |
| PE + 13-hydroperoxyoctadecadienoic acid and other oxidized poly unsaturated fatty acids (PUFAs) followed by phospholipase | LC-MS and NMR | [ | |
| Different species of PE + 4-hydroxy- | GC-MS, TLC, HPLC, and NMR | Aldehydes-PE. Different PE species are differently targeted by fatty aldehydes | [ |
| PE + Isoketals (IsoK) | LC-ESI-MS | IsoK-PE pyrrole adducts and IsoK-PE Schiff base adducts | [ |
| Fatty aldehydes released from plasmalogens after oxidation of cerebral cortex homogenates | GC-MS | [ | |
| PE + Glucose + Potential “antiglycative” compounds (protein glycation inhibitors, antioxidants, vitamins, | LC-ELSD-MS | Amadori-PE. Pyridoxal 5′-phosphate and pyridoxal/vitamin B6 derivatives) are the most effective antiglycative compounds | [ |
| Acetoacetate + brain aminophospholipids | TLC and spectrophotometry | UV spectroscopy at 280 nm | [ |
| Acetaldehyde-PE | Density functional theory study | Schiff base formation between PE and acetaldehyde | [ |
| Liposomes and human high density lipoprotein (hHDL) particles in oxidative conditions | LC-MS | Isolevuglandins (IsoLGs)-, MDA-, 4.HNE-, | [ |
| hLDL | Fluorimeter | Fluorescent chromophores AGEs-lipids (Ex 360 nm, Em 440 nm) | [ |
| Rat liver aminophospholipids | GC-MS | Amadori aminophospholipids (as 5-(hydroxymethyl)-2-furfuraldehyde; 5-HMF) | [ |
| Liver mitochondria from mammalian species | GC-MS | Carboxymethyl-ethanolamine (as marker of CM-PE) | [ |
| hRBCs | TLC, HPLC, NMR, FAB-MS | Deoxy- | [ |
| RBC membranes | GC-MS | Glycation and carboxymethylation of aminophospholipids (PE and PS) | [ |
| Glucose/lactose + PE; foods and biological samples Presence in foods (e.g., infant formula, chocolate) and in rat plasma | HPLC-UV (labeling with 3-methyl-2-benzothiazolinone hydrazone) | Glycated-PE and lactose-PE | [ |
| RBC and LDL | LC-MS and NMR | [ | |
Figure 3Advanced glycation end products (AGEs)-lipid products resulting from the Maillard reaction.
Summary of studies on physico-chemical effects of non-enzymatic aminophospholipid modification by carbonyl-amine reactions.
| Analytical approach | Marker | Finding | Ref. | |
|---|---|---|---|---|
| Rat and human urine | NMR and HPLC | Direct evidence for oxidative decomposition of phospholipids by lipid peroxidation | [ | |
| Rat and human urine | NMR and HPLC | Direct evidence for oxidative decomposition of phospholipids by lipid peroxidation | [ | |
| Glucose + PE/hLDL | Fluorimeter | Fluorescent lipid advanced glycosylation (Ex 360 nm, Em 440 nm) | Increase of fluorescence associated with the progressive oxidative modification of unsaturated fatty acid residues | [ |
| Lipids (PE and PS) and hLDL-advanced glycosylation | GC-MS | 4-hydroxyhexenal and 4-hydroxynonenal | Lipids-AGE formation in close proximity to unsaturated fatty acyl groups leads to lipid peroxidation | [ |
| Unilamellar vesicles with PE and PC + glyceraldehyde | Time-resolved fluorescence spectroscopy | Aminophospholipid glycation increases the head-group hydration and lipid order in both regions of the membrane and lipid glycation is accompanied of lipid oxidation | [ | |
| Atherosclerotic plaques collected from both diabetic and non-diabetic subjects | LC-ESI-MS | Glycated PE | Glycated aminophospholipids are the major LDL glycation products and increase LDL susceptibility to oxidation | [ |
| Model systems and egg yolk products | LC-ESI-MS | Identification of PE-linked glucosylamines (Schiff-PE), Amadori products (Amadori-PE), 5-hydroxymethylpyrrole-2-carbaldehydes (Pyrrole-PE), and carboxymethyl- (CM-PE) as well as carboxyethyl-(CE-PE) derivatives | Possible influence on emulsifying properties and oxidation resistance | [ |
| Amadori-PE + linoleic acid | LC-MS and colorimetry | TBARs and lipid hydroperoxides | Glycated-PE trigger lipid peroxidation via free radical reactions | [ |
| RBCs from diabetic and healthy individuals | LC-ESI-MS | Schiff-PEs and Amadori-PEs, and detection of pyrrole-PE, CM-PE and CE-PE | Increase in diabetes; glycated PE promotes lipid peroxidation of biomembranes | [ |
| Different species of PE + 4-HNE/4-HDDE/4-HHE | GC-MS, TLC, HPLC, and NMR | Aldehydes-PE | Different PE species are differently targeted by fatty aldehydes: the higher their hydrophobicity, the higher the amount of adducts made | [ |
| PE/PC monolayers + 4-HNE | Alternating current (AC) polarography | Physico-chemical state of a condensed PE-containing phospholipid monolayer and its interaction with apo A-I | 4.HNE-PE does not alter monolayer stability, but decreases apo A-I insertion into the monolayer | [ |
| PC/PE mixture + Glucose + isolated membrane proteins | Lipid-protein interactions | Amadori-PE and Amadori-proteins, and lipid-protein interaction parameters | Lipid glycation decreases the affinity of lipids for membrane proteins, induces structural rearrangements in the protein that makes it more sensitive to thermal unfolding and decreases the affinity between proteins and the surrounding phospholipids. | [ |
| PE + Glucose + oxidative conditions | LC-ESI-MS | Glycated-PE + oxidation products | Oxidation of glycated-PE occurred more quickly than the oxidation of non-glycated-PE probably because of the existence of more oxidation sites derived from glycation of polar head group. | [ |
| PE + Glucose + oxidative conditions | LC-MS-MS | Identification of free radicals in oxidized and glycoxidized PE | Presence of several sites susceptible to oxidation in glycated-PE which may be responsible for the increase in the oxidative reaction rate occurring in glycated compounds | [ |
Figure 4Potential effects of aminophospholipid modification by carbonyl-amine reactions in biological membranes.
Summary of studies on biological effects of non-enzymatic aminophospholipid modification by carbonyl-amine reactions.
| Experimental model | Analytical approach | Marker | Finding | Reference |
|---|---|---|---|---|
| MDA+RBCs and | TLC | MDA:phospholipid adducts | Lipid peroxidation and MDA accumulation disturb organization of PS and PE in the human erythrocyte membrane bilayer | [ |
| Erythrocytes of phenylhydrazine-treated rats | TLC | MDA:phospholipid adducts | Externalization of PS and PE in the membrane bilayer and hypercoagulability | [ |
| Glucose-treated RBC | TLC | MDA:phospholipid adducts | Increase adduct formation and osmotic fragility in human RBCs | [ |
| hRBCs from different age groups + MDA or H2O2 treatment | Aminophospholipid translocase activity | Decrease with age (defects in endogenous lipid asymmetry observed in aged human RBCs may be due to altered activity of the translocase) | [ | |
| Lipid extracts from platelet incubated PE + PS + 4-HNE | LC-MS | PE-4-HNE compounds | Formation in cell membranes that could alter the phospholipase-dependent cell signalling | [ |
| Glycated-PE LDL + THP1 cells (macrophages) | Cell culture, LC-ESI-MS | Glycated PE | Glycated-PtdEtn promotes macrophage uptake of LDL and accumulation of cholesteryl esters and triacylglycerols | [ |
| Oxidized-LDL + platelets | TLC | Aldehyde-PE | Modified PE as the active component of oxidized LDL particles elicit a pronounced prothrombotic response by increasing the activity of the platelet prothrombinase complex | [ |
| PE + 4-HNE and 4-HDDE (4-hydroxy-2E,6Z-dodecadienal) | TLC and GLC | 4-HNE-PE and 4-HDDE-PE | Modified PE is poor substrate for secreted phospholipase A2 | [ |
| Human Plasma | TLC and GLC | 4-HNE-PE and 4-HDDE-PE | Potential alteration of phospholipid-dependent cell signaling | [ |
| Amadori-PE + endothelial cells (HUVEC) | Cell culture | Cell proliferation, migration, and tube formation, and secretion of matrix metalloproteinase 2 (MMP-2) | Glycated-PE promotes vascular disease as a result of its angiogenic activity on endothelial cells | [ |
| Human blood platelets | GC-MS | 4-HHE-, 4-HNE-, and 4-HDDE-PE | [ |
Summary of studies on physiological and pathological effects of non-enzymatic aminophospholipid modification by carbonyl-amine reactions.
| Experimental model | Analytical approach | Marker | Finding | Reference |
|---|---|---|---|---|
| Aged RBC | Fluorimeter | Fluorescent chromophores (Ex 390–400 nm, Em 460 nm) | Increase with aging Altered physical and biochemical properties of aging cells (polymerization of plasma membrane proteins) | [ |
| Lipids extracts from different tissues (heart, brain, liver, testis, kidney, adrenal cortex) | Fluorimeter | Fluorescent chromophores | Increase with aging, and in pathological conditions (e.g., diabetes, hyperlipidemia) | [ |
| RBC fromiron-deficient infants and animals | Thin Layer Chromatography (TLC) | Schiff’s base adduct due to reaction MDA + PS/PE | Decrease RBC survival | [ |
| RBC from the “sickle cell disease” | Fluorimeter and TLC | Fluoresecent chromophores & MDA:aminophospholipid adducts | Increase adduct formation in sickle cell disease | [ |
| Lipid extracts of the human cataractous and normal lenses | Fluorimeter and TLC | Fluoresecnt chromophores (Ex 365 nm, Em 460 nm) and MDA: aminophospholipid adducts | Increase in human senile cataract | [ |
| Aged human RBC membranes | Fluorimeter and TLC | Fluorescent chromophores & MDA: aminophospholipid adducts | Increase with aging | [ |
| RBC from diabetic patients | TLC | MDA:phospholipid adducts | Increase adducts in diabetes | [ |
| humanRBC (hRBC) from different age groups + MDA or H2O2 treatment | Aminophospholipid translocase activity | Decrease with age (defects in endogenous lipid asymmetry observed in aged human RBC may be due to altered activity of the translocase) | [ | |
| LDL from diabetic patients | Fluorimeter | Increase in diabetes | [ | |
| Rat liver aminophospholipids in streptozotocin-induce diabetic rats | GC-MS | Amadori aminophospholipids (as 5-(hydroxymethyl)-2- furfuraldehyde; 5-HMF) | Increase in diabetes | [ |
| RBC and plasma from diabetic and control subjects | LC-ESI-MS | Glycated aminophospholipids | Increase in diabetes | [ |
| Urine from diabetic and control subjects | GC-MS | Carboxymethylethanolamine (as marker of CM-PE) | No increase in diabetes | [ |
| Liver mitochondria from mammalian species | GC-MS | Carboxymethyl-ethanolamine (as marker of CM-PE) | CM-PE formation at mitochondrial level is associated with animal lifespan | [ |
| hRBC from diabetic and control subjects | GC-MS | Adducts formed | [ | |
| hLDL from plasma and atherosclerotic aorta | GC-MS | pHA-ethanolamine | Increase of pHA-PE in human atherosclerotic intima | [ |
| RBC from diabetic and healthy individuals | LC-ESI-MS | Schiff-PEs, Amadori-PEs, pyrrole-PE, CM-PE and CE-PE | Increase in diabetes; glycated PE promotes lipid peroxidation of biomembranes | [ |
| Amadori-PE of a lipid extract from diabetic plasma | QTRAP LC-MS-MS | Amadori-PE | Increase in diabetes | [ |
| Plasma from: healthy volunteers, chronic hemodyalisis patients, Type II diabetic patients without chronic hemodialysis, and Type II diabetic patients with chronic hemodialysis | HPLC-MS-MS | Amadori-PE | Increase of Amadori-PE in diabetes with or without chronic hemodialysis | [ |
| Plasma from streptozotocin-diabetic rats | LC-ELSD-MS | Amadori-PE | Increase in diabetes and decrease in streptozotocin-induced diabetes and pyridoxal-treated rats | [ |
| Retinas of streptozotocin-induced diabetic rats | GC-MS | 4-HHE-, 4-HNE-, and 4-HDDE-PE | Increase in diabetic animals | [ |
| hRBC and blood plasma from healthy subjects and diabetic patients | LC-MS-MS | CM-PE and CE-PE as AGE-PE, and Amadori-PE | No significant differences were observed in AGE-PE in RBC and plasma, whereas Amadori-PE concentrations were higher in diabetic patients | [ |
| Blood plasma, kidney, RBCs, liver, pancreas, cerebrum, and cerebellum from streptozotocin-induced diabetes rats | LC-MS-MS | Amadori-PE | Increase in diabetes. Amadori-PE(18:0–20:4) is the PE species that acts as the most sensitive indicator | [ |